Compass Therapeutics (NASDAQ:CMPX) Posts Earnings Results, Meets Expectations

Compass Therapeutics (NASDAQ:CMPX) posted its quarterly earnings data on Monday. The company reported ($0.12) earnings per share for the quarter, meeting the consensus estimate of ($0.12), Zacks reports.

Compass Therapeutics Trading Up 2.2%

Shares of CMPX opened at $1.82 on Monday. The stock has a market cap of $251.68 million, a P/E ratio of -4.92 and a beta of 1.40. The company has a 50-day moving average of $2.00 and a two-hundred day moving average of $2.10. Compass Therapeutics has a 12-month low of $0.77 and a 12-month high of $4.08.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on CMPX. D. Boral Capital reiterated a “buy” rating and set a $32.00 target price on shares of Compass Therapeutics in a research note on Monday, April 28th. Leerink Partnrs raised Compass Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, April 1st. Leerink Partners raised Compass Therapeutics from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $4.00 to $6.00 in a research report on Wednesday, April 2nd. Jefferies Financial Group increased their price target on Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, February 10th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $24.00 price target on shares of Compass Therapeutics in a report on Monday, April 21st. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $13.13.

Insider Buying and Selling

In other news, Director Carl L. Gordon sold 3,571,428 shares of the business’s stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total value of $5,678,570.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jonathan Anderman purchased 20,000 shares of the business’s stock in a transaction dated Monday, April 7th. The stock was bought at an average cost of $1.54 per share, with a total value of $30,800.00. Following the completion of the acquisition, the insider now owns 21,000 shares of the company’s stock, valued at approximately $32,340. The trade was a 2,000.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 28.50% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.